Prostate cancer is the second most common type of cancer in men and 1 in 8 American men will be diagnosed with prostate cancer in his lifetime.
This year alone, almost 250,000 men are expected to be diagnosed with prostate cancer. Men aged 40 and above need to take charge of their health and understand what testing options are available.
Prostate specific antigen, or PSA, remains the most common test for screening for prostate cancer, but PSA is not very specific and can be affected by benign prostatic hyperplasia (BPH), infection, age, medications, and even bicycle riding. This lack of specificity has led to over-detection of men that were not at risk of clinically significant prostate cancer, resulting in biopsy which can lead to complications such as incontinence, sexual dysfunction, bleeding, and infection.
An effective test
The ExoDx™ Prostate (EPI) Test can help the prostate biopsy decision.
The EPI test is a simple, non-invasive urine test and doesn’t require a digital rectal exam (DRE). It is designed to provide a personalized risk score to help a man and his physician determine the risk of aggressive prostate cancer if prostate biopsy is performed. The non-invasive EPI test is proven to give confidence to defer or proceed to a prostate biopsy.
The test can be ordered by any physician and is now available as an At-Home Collection Kit.
One patient says, “I’m 61 and my PSA stays between 6–6.5ng/mL. I discussed the pros and cons of getting a biopsy with my doctor, and then learned about the ExoDx test. We decided to get the test. My result came back below the cut-point, and now he doesn’t want to see me for six months!”
Ask your doctor about the ExoDx Prostate test or visit https://www.exosomedx.com/patients/exodx-prostate-test today.